# A Study of MSB0254 Injection in Advanced Solid Tumors

> **NCT04381325** · PHASE1 · TERMINATED · sponsor: **Suzhou Transcenta Therapeutics Co., Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** MSB0254 Injection

## Key facts

- **NCT ID:** NCT04381325
- **Lead sponsor:** Suzhou Transcenta Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-01
- **Primary completion:** 2022-06-08
- **Final completion:** 2022-06-08
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04381325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04381325, "A Study of MSB0254 Injection in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04381325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*